0000000001029240

AUTHOR

Icro Meattini

showing 6 related works from this author

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the r…

2021

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-l…

Oncologymedicine.medical_specialtyAdvanced breastT-DM1Treatment outcomeLapatinibBreast cancerpertuzumabInternal medicineMedicinelapatinibRC254-282advanced breast cancerbusiness.industryHuman epidermal growth factoradvanced breast cancer; HER2-positive; lapatinib; pertuzumab; sequence; T-DM1Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancersequencemedicine.diseaseHER2-positiveOncologyObservational studyPertuzumabbusinessmedicine.drug
researchProduct

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

2021

Breast cancer (BC) heterogeneity is composite in nature, with a wide variety of factors concurring to define several pathological entities, which differ by clinical presentation, pathologic features, therapy administered, and inherent outcomes1. Additional sources of breast cancer heterogeneity may raise during the disease course. In BC patients whose disease was initially diagnosed in the early stage and subsequently progressed with metastatic involvement of one single or multiple site/s, the molecular characteristics of metastatic lesions do not necessary mimic those of the disease initially diagnosed. A well-depicted molecular landscape is crucial for subtype definition, prognostic evalu…

0301 basic medicineOncologyCancer therapyReceptor ErbB-2medicine.medical_treatmentAdo-Trastuzumab Emtansineprogesterone receptorSettore MED/060302 clinical medicinehuman epidermal growth factor receptor 2 (HER2)Antineoplastic Combined Chemotherapy ProtocolsestrogenNeoplasm Metastasisskin and connective tissue diseasesMultidisciplinaryBrain NeoplasmsQRMiddle AgedPrognosisMetastatic breast cancerNeoplasm Metastasi030220 oncology & carcinogenesisMedicineFemalePertuzumabmetastatic breast cancerReceptors ProgesteroneBreast NeoplasmHER2 positivitymedicine.drugHumanAdultmedicine.medical_specialtymedicine.drug_classSciencetrastuzumab-emtansineBreast Neoplasmsmetastatic breast cancer; HER2 positivity; cancerArticleDisease-Free SurvivalBrain Neoplasm03 medical and health sciencesBreast cancerbreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicineProgesterone receptormedicineHumanscancerbreast cancer; human epidermal growth factor receptor 2 (HER2); pertuzumab; trastuzumab-emtansine; estrogen; progesterone receptorneoplasmsAgedChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancermedicine.diseaseHER2-positiveBreast cancer; oncology; radiotherapy; chemotherapy; HER2Radiation therapy030104 developmental biologyEstrogenbusinessprognostic relevance
researchProduct

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95…

AdultOncologyEribulin Mesylatemedicine.medical_specialtyeribulin mesylatemedicine.medical_treatmentTriple Negative Breast Neoplasmschemotherapytriple negative metastatic breast cancer03 medical and health scienceschemistry.chemical_compound0302 clinical medicineadjuvantInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapy; Efficacy outcomes; Eribulin mesylate; Toxicity outcomes; Triple negative metastatic breast cancerProgression-free survivalFuransAdverse effectTriple-negative breast cancerAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapybusiness.industryRetrospective cohort studyGeneral MedicineKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerNeoadjuvant TherapyProgression-Free SurvivalchemistryChemotherapy AdjuvantFemale030211 gastroenterology & hepatologytoxicity outcomesefficacy outcomeschemotherapy; efficacy outcomes; eribulin mesylate; toxicity outcomes; triple negative metastatic breast cancer; adult; aged; aged; 80 and over; antineoplastic combined chemotherapy protocols; chemotherapy; adjuvant; female; furans; humans; ketones; middle aged; neoadjuvant therapy; neoplasm staging; progression-free survival; retrospective studies; triple negative breast neoplasmsbusinessResearch PaperEribulinInternational Journal of Medical Sciences
researchProduct

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

2020

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 70…

0301 basic medicineOncologyPhysiologyReceptor ErbB-2Clinical BiochemistryAdo-Trastuzumab EmtansineSettore MED/06body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansinechemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalAged 80 and overeducation.field_of_studyUnivariate analysisMiddle AgedMetastatic breast cancerProgression-Free SurvivalQuartile030220 oncology & carcinogenesisHER2-positive metastatic breast cancerDisease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialtyPopulationBreast Neoplasmsbody mass indexAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineHumansObesityeducationAgedtrastuzumab emtansinebusiness.industrynutritional and metabolic diseasesCell BiologyOverweightmedicine.disease030104 developmental biologychemistryTrastuzumab emtansineMED/06 - ONCOLOGIA MEDICAbusinessBody mass index
researchProduct

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HE…

2020

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression‐free survival at first‐line (mPFS1) was 12 months. Pertuzumab as first‐line conferred longer mPFS1 compared to other first‐line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second‐line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T‐DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing b…

OncologyCancer ResearchMultivariate analysisSettore MED/06 - Oncologia MedicaReceptor ErbB-2T-DM1Estrogen receptor0302 clinical medicineErbB-2TrastuzumabReceptorsAntineoplastic Combined Chemotherapy Protocols80 and overMolecular Targeted TherapyNeoplasm MetastasisCancer Therapy and PreventionProgesteroneAged 80 and overadvanced breast cancerTumorreal worldMiddle AgedPrognosisMetastatic breast cancerImmunohistochemistryGene Expression Regulation NeoplastictrastuzumabOncologyReceptors Estrogen030220 oncology & carcinogenesisImmunohistochemistryFemaleadvanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Gene Expression Regulation NeoplasticPertuzumabReceptors ProgesteroneHER2 positive; T-DM1; advanced breast cancer; pertuzumab; real world; trastuzumabmedicine.drugReceptorAdultHER2 positivemedicine.medical_specialtyT‐DM1advanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; chemotherapyBreast Neoplasms03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineBiomarkers TumorHumansAgedNeoplasm StagingNeoplasticbusiness.industrymedicine.diseaseEstrogenSettore CHIM/08 - Chimica FarmaceuticaGene Expression RegulationMED/06 - ONCOLOGIA MEDICAbusinessBiomarkersHormone
researchProduct

sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observati…

2021

Supplemental material, sj-docx-1-tam-10.1177_17588359211059873 for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting by Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D���Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D���Auria, Anna Ceribe…

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct